RE:Looking towards a Q2/21 Preliminary Report (?)I think your revenue fiqure is pretty accurate and guided by the company as well. So approx $26million US.
The Company is pleased to share the following current financial and operating metrics. Please note these metrics do not include potential future acquisitions or ongoing organic growth initiatives:
• Run-Rate Revenue of USD$100-$105 million
• 120,000 current active patients
• 17,000 unique referrals
• 51 locations across 11 U.S. States
More important in my opinion, will be free cash flow # or Ebita plus aquisition expenses or ebitda plus aquisition expenses less equipment capex. I think more investors in this industry are recoginizing this metrics. For a roll up, it is important that the company's own cash flow, helps contribute to aquisitions and equipment purchases. IE Less cash burn and delays need for dilutive financings.